Home/Pipeline/Tau/pTau Biomarker Program

Tau/pTau Biomarker Program

Alzheimer's Disease

Pre-clinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Pre-clinical

Status

Active

Company

NeuroDex

About NeuroDex

NeuroDex is a private, pre-revenue diagnostics company founded in 2019, specializing in biomarker development for neurological disorders through its neuron-derived exosome (NDE) technology. The company offers a suite of biomarker services and panels targeting key pathological proteins (e.g., α-Syn, TDP-43, Tau) to support pharmaceutical partners in clinical trials and translational research. With a team led by CEO/CSO Erez Eitan and operations in Boston, NeuroDex positions itself at the intersection of advanced diagnostics and the growing precision neurology market, though it faces risks typical of early-stage biotechs, including platform validation and funding needs.

View full company profile

Therapeutic Areas

Parkinson's Disease Alzheimer's Disease Amyotrophic Lateral Sclerosis (ALS)Frontotemporal Dementia Neuroinflammation Brain Injury

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active